A Detailed Analysis of Cirrhosis Management Market by Antiviral Medications for Hepatitis B & C, Treating Cirrhosis Causes, Corticosteroids, Symptomatic Treatment, Analgesics, Treatment of Portal Hypertension (Beta-Blockers, Nitrates), Treatment of Edema and Ascites (Diuretics, Antibiotics), Avoid Complications, Banding Procedures/Band Ligation of Varics, Dialysis, Treatment of Osteoporosis, Vaccination for Flu and Other Complications, Liver Transplantation
Awareness Programs and Increased Investment in Research and Development for the Creation of New Drug Molecules are Expected to Help the Market Progress- Explore FMI's extensive analysis of the Cirrhosis Management Landscape
Cirrhosis Management Market Snapshot (2023 to 2033)
Valued at US$ 725 million in 2023, the global market for cirrhosis management is likely to exhibit a CAGR of 3.8% during the forecast period, reaching US$ 1,052.3 million by 2033. The market exhibited a compounded growth rate of 2.7% from 2018 to 2022. Expansion of the market can be attributed to the increasing incidences of liver cirrhosis due to rise in the hepatitis infections across the globe.
Data Points
Key Statistics
Expected Base Year Value (2022)
US$ 701.8 million
Projected Market Value (2023)
US$ 725 million
Anticipated Forecast Value (2033)
US$ 1,052.3 million
Estimated Growth Rate (2023 to 2033)
3.8%
Cirrhosis is a late-stage result of liver disease and its complications. Common causes of Cirrhosis include alcohol abuse, hepatitis, and nonalcoholic fatty liver disease. Treatment and Management of Cirrhosis depends on the cause of the disease and how much damage exists. Liver transplantation may be an option if one’s liver is failing, due to disease.
As per the National Center for Biotechnology Information (NCBI), liver disease claims about 2 million deaths globally, every year. Currently, Cirrhosis is the 11th most cause of death. Due to aggravating situation, players in the market are taking various initiatives to tackle the worsening condition, which is expected to benefit the industry in the coming time.
In September 2019, Versantis raised a Series B of € 14.6 Million to develop its treatment for late-stage liver cirrhosis in a phase II trial. Post the II trial, the company announced that it is projected to use the funds to launch a phase IIa trial of the treatment in early 2020. Such factors are expected to benefit the cirrhosis management market in the forecast period.
Increasing incidences of liver cirrhosis due to rise in the hepatitis infections across the globe is one of the major factors that is expected to accelerate the growth of the global Cirrhosis Management Market over the analysis period.
On the contrary, the high cost associated with drug development is one of the major factors that is expected to hinder the growth of the cirrhosis management market during the forecast period.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Which Are Some Prominent Drivers Spearheading Cirrhosis Management Market Growth?
The increase in the occurrence of liver cirrhosis due to the rise in hepatitis infections is one of the major factors that is anticipated to boost the growth of the global liver cirrhosis management market during the forecast period.
The rise in the number of people suffering from liver cirrhosis can be attributed to rapidly changing lifestyles such as an increase in alcohol consumption and an unbalanced diet. Hence, the rise in the prevalence of the disease is projected to fuel the growth of the global market during the forecast period.
According to the National Center for Biotechnology Information (NCBI), around 2 billion people consume alcohol worldwide, and upwards of 75 million are diagnosed with alcohol-use disorders and are at risk of alcohol-associated liver disease. Nearly 2 billion adults are obese or overweight and over 400 million have diabetes; both of which are risk factors for non-alcoholic fatty liver disease and hepatocellular carcinoma.
An increase in awareness programs and a rise in research & development investment for the development of new drug molecules are expected to augment the global liver cirrhosis management market in the forthcoming years. In addition, the rise in government-driven initiatives in the field of liver cirrhosis treatment is another factor that is expected to propel the global market shortly.
According to WHO, alcohol consumption is expected to cause 20% to 50% of liver cirrhosis cases. Also, the increasingly obese populace is expected to grow the risk of non-alcoholic fatty liver disease caused due to build-up of fat in the liver. Other vital factors contributing to the market growth include increased R&D, growing public awareness, and expanding geriatric population.
The increasing initiative of players to launch innovative tools is projected to be an effective factor in developing the market. For instance, in March 2022, Echosens, a high-tech company offering the FibroScan ® portfolio of solutions, announced the launch of FibroScan GO, a cost-effective tool for screening lover health and improving liver health management at the point of care for primary care practices. Attributed to such factors, the market is anticipated to grow significantly in the forecast period.
What Are the Challenges Faced by the Cirrhosis Management Industry?
Stringent regulatory approvals and delayed approvals for novel drugs and vaccines are one of the major factors that are anticipated to impede the growth of the cirrhosis management market during the forecast period. Also, side effects associated with products (fever, depression, and fatigue) is another vital factor that is expected to hamper the market growth in the coming time.
Moreover, the high cost associated with drug development is also a major factor that is expected to limit the growth of the cirrhosis management market over the analysis period. However, ongoing research studies and clinical trials for the treatment of liver disease are expected to act as a significant counter to the hampering causes and propel market growth in the coming time.
For instance, in March 2022, Siemens Healthineers launched Enhanced Liver Fibrosis (ELF) Test in the United States. It provides clinical access to the minimally invasive prognostic tool. Thus, the market is likely to expand significantly in the coming time.
Find your sweet spots for generating winning opportunities in this market.
Why Is North America Emerging as An Opportunistic Cirrhosis Management Market?
Region
North America
Market Share % (2022)
39.2%
In terms of regional platforms, North America holds the largest market share in the Cirrhosis Management market. The region gained a market share of 39.2% share in 2022. Developed nations like the United States, Canada, and others are expected to make the maximum contribution to strengthen the growth of the cirrhosis management industry. Domination of the region can be attributed to the presence of major players like Astellas Pharma Inc., Mylan, AbbVie Inc., Merck & Co., Inc., and others.
Ongoing development in the field is anticipated to offer significant results to the market. For instance, in December 2019, Gilead Sciences, Inc. announced topline results from the 48-week, Phase 2 ATLAS study of combination and monotherapy investigational treatments for advanced fibrosis due to Nonalcoholic Steatohepatitis (NASH).
The study resulted in the improvement of various measures of fibrosis and liver injury with the investigational first cost at and cilofexor. Attributed to such factors, the market in North America is expected to develop significantly in the forecast period.
Moreover, a favorable reimbursement scenario, an increase in research and development investments in pharmaceutical companies & research institutes for new drug development, and the presence of major players in the region are some major factors that are expected to fuel the market growth during the forecast period.
How Is Europe Contributing to the Growth of the Cirrhosis Management Market?
Region
(2022)Europe
Market Share %
26.7%
According to Future Market Insights, Europe is expected to hold significant growth opportunities for cirrhosis management and reached a share of 26.7% in 2022.
According to the WHO, about 1.8% of all deaths in Europe are caused due to liver cirrhosis. Continuous efforts taken by the players in the market are likely to provide a significant boost to market growth in the coming time. For instance, in March 2021, A-Tango Consortium, a five-year project that receives funding from European Union’s Horizon 2020, was launched.
A-Tango Consortium will perform Phase II clinical studies of an innovative therapeutic strategy that targets inflammation and improves liver regeneration, the novel therapy is called G-TAK. Owing to such innovations in the region, the European market is anticipated to augment significantly in the forecast period.
Europe is likely to be the second largest market for liver cirrhosis treatment during the forecast period, owing to a rise in awareness about new treatment options and a developed regulatory framework in the region.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Where Does Asia-Pacific Region Stand in The Cirrhosis Management Market?
Countries
Market Forecast % (2023 to 2033)
China
4.3%
India
4.1%
According to Future Market Insights, Asia-Pacific is expected to grow with lucrative growth opportunities for the cirrhosis management industry.
Asia-Pacific is anticipated to witness notable growth, owing to a rise in research and development activities, a surge in liver diseases, unmet medical demands, and an increase in investments in the healthcare sector in the region.
Moreover, an increase in the consumption of alcohol, an unhealthy lifestyle leading to obesity & weight gain, the presence of key players, and a rise in healthcare expenditure in the region are some of the major factors that are anticipated to augment the growth of the cirrhosis management market over the analysis period.
In addition, the rise in the prevalence of liver diseases and improving healthcare infrastructure are other factors propelling the market growth in the region.
How Is Middle East & Africa Contributing to the Growth of the Cirrhosis Management Market?
According to Future Market Insights, the Middle East & Africa are expected to provide significant growth opportunities for the cirrhosis management industry.
The Middle East & Africa is expected to have significant growth in the cirrhosis management industry during the forecast period. The rising patient population suffering from liver cirrhosis is one of the major factors that is anticipated to escalate the market growth in the region.
The region is projected to have lucrative growth opportunities, attributed to the rapidly developing healthcare amenities among Saudi Arabia, Oman, and Qatar. Over 200,000 deaths took place in Sub-Saharan Africa due to liver diseases resulting in liver cirrhosis. More than 80% of Africa’s liver disease burden is due to endemic blood-borne virus infections like HIV, hepatitis B, and hepatitis C.
Additionally, the market Middle East & Africa is anticipated to expand at a steady pace, attributed to the presence of rapidly developing economies and evolving healthcare infrastructure in these regions.
Role Of Start-Ups in the Cirrhosis Management Market
There are many prominent market players in the Cirrhosis Management Market such as Galea Therapeutics, Akero Therapeutics, Inorbit Therapeutics, Ochre Bio, Ezra, Jetra Therapeutics, Moderna Therapeutics, Translate Bio, Promethera Biosciences, and AgomAb Therapeutics, among others, which are working hand-in-hand to provide the best-in-class Cirrhosis Management for enhancing the global arena.
However, there are many global start-ups in the Cirrhosis Management Market, that are stepping forward in matching the requirements of the Cirrhosis Management domain.
Founded in 2017, Akero Therapeutics is a clinical-stage biopharmaceutical company focused on delivering transformational medicines to patients with high unmet medical needs. The company aims to advance its lead program efruxifermin (EFX), to provide a powerful new treatment for patients with NASH, a disease for which there are currently no marketed therapies.
Market Competition
Some of the key participants present in the global Cirrhosis Management market include Theravance Biopharma R&D, Alliancells Bioscience Corporation Limited, B. Braun Medical Inc., Conatus Pharmaceuticals Inc., Merck Sharp & Dohme Corp., Stempeutics Research Pvt Ltd, Epic Research & Diagnostics, Inc., Inc., and NovaShunt AG among others.
Attributed to the presence of such a high number of participants, the market is highly competitive. While global players such as Theravance Biopharma R&D, Alliancells Bioscience Corporation Limited, and B. Braun Medical Inc., account for a considerable market size, several regional-level players are also operating across key growth regions, particularly in North America.
Recent Key Developments in the Market Include
In February 2021, B.Braun Medical Inc., an eminent in infusion therapy and pain management, announced that it received approval from the United States FDA for the first and only Acetaminophen Injection available in various doses. Acetaminophen Injection contains acetaminophen, which has been associated with cases of acute liver failure, resulting in liver transplant, and death.
In September 2021, Merck (MSD) announced that its antibody Keytruda met the primary endpoint of overall survival (OS) in Phase III KEYNOTE-394 clinical trial in Asian patients with advanced hepatocellular carcinoma (HCC), the most common form of primary liver cancer.
Report Scope
Report Attributes
Details
Growth Rate
3.8% CAGR from 2023 to 2033
Market Value in 2023
US$ 725 million
Market Value in 2033
US$ 1,052.3 million
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
US$ million for Value
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
Treatment
Disease Indication
End User
Region
Regions Covered
North America
Latin America
Europe
Asia Pacific
Middle East & Africa
Key Countries Profiled
The United States
Canada
Brazil
Mexico
Germany
The United Kingdom
France
Spain
Italy
China
Japan
South Korea
Malaysia
Singapore
Australia
New Zealand
GCC
South Africa
Israel
Key Companies Profiled
B. Braun Medical Inc.
Alliancells Bioscience Corporation Ltd.
Histogen Inc.
Stempeutics Research Pvt. Ltd.
Epic Research & Diagnostics Inc.
Theravance Biopharma R&D Inc.
Sequana Medical AG
Customization Scope
Available upon Request
Key Segments Profiled in the Cirrhosis Management Industry Survey
By Treatment:
Treating Cirrhosis Causes
Antiviral Medications for Hepatitis B & C
Corticosteroids
Symptomatic Treatment
Analgesics
Treatment of Portal Hypertension (Beta-Blockers, Nitrates)
Treatment of Edema and Ascites (Diuretics, Antibiotics)
Avoid Complications
Banding Procedures/Band Ligation of Varics
Dialysis
Treatment of Osteoporosis
Vaccination for Flu and Other Complications
Liver Transplantation
By Disease Indication:
Alcoholic Liver
Non-Alcoholic Liver
By End User:
Hospitals
Ambulatory Surgical Centers
Research Institutes
Dialysis Centers
Clinics
Other Settings
By Region:
North America
Latin America
Europe
Asia Pacific
Middle East & Africa
Frequently Asked Questions
The leading Asian nations in the market for cirrhosis management are China, India, Japan, and South Korea.
The primary consumer of the cirrhosis management market is the healthcare sector.
The cirrhosis management market growth is predicted to be 4.3% in China and 4.1% in India by 2033
The cirrhosis management market is currently valued at US$ 1052.3 million.
Cirrhosis management is anticipated to be worth USD 1,052.3 million by 2033.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
5.3.1. Treating Cirrhosis Causes
5.3.2. Antiviral Medications for Hepatitis B & C
5.3.3. Corticosteroids
5.3.4. Symptomatic Treatment
5.3.5. Analgesics
5.3.6. Treatment of Portal Hypertension
5.3.7. Treatment of Edema and Ascites
5.3.8. Avoid Complications
5.3.9. Banding Procedures/Band Ligation of Varics
5.3.10. Dialysis
5.3.11. Treatment of Osteoporosis
5.3.12. Vaccination for Flu and Other Complications
5.3.13. Liver Transplantation
5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Indication
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Disease Indication, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Indication, 2023 to 2033
6.3.1. Alcoholic Liver
6.3.2. Non-Alcoholic Liver
6.4. Y-o-Y Growth Trend Analysis By Disease Indication, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Disease Indication, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
7.3.1. Hospitals
7.3.2. Ambulatory Surgical Centers
7.3.3. Research Institutes
7.3.4. Dialysis Centers
7.3.5. Clinics
7.3.6. Other Settings
7.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Western Europe
8.3.4. Eastern Europe
8.3.5. South Asia and Pacific
8.3.6. East Asia
8.3.7. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Treatment
9.2.3. By Disease Indication
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment
9.3.3. By Disease Indication
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Treatment
10.2.3. By Disease Indication
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment
10.3.3. By Disease Indication
10.3.4. By End User
10.4. Key Takeaways
11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. UK
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Western Europe
11.2.2. By Treatment
11.2.3. By Disease Indication
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment
11.3.3. By Disease Indication
11.3.4. By End User
11.4. Key Takeaways
12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Poland
12.2.1.2. Russia
12.2.1.3. Czech Republic
12.2.1.4. Romania
12.2.1.5. Rest of Eastern Europe
12.2.2. By Treatment
12.2.3. By Disease Indication
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment
12.3.3. By Disease Indication
12.3.4. By End User
12.4. Key Takeaways
13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Bangladesh
13.2.1.3. Australia
13.2.1.4. New Zealand
13.2.1.5. Rest of South Asia and Pacific
13.2.2. By Treatment
13.2.3. By Disease Indication
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Treatment
13.3.3. By Disease Indication
13.3.4. By End User
13.4. Key Takeaways
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Treatment
14.2.3. By Disease Indication
14.2.4. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Treatment
14.3.3. By Disease Indication
14.3.4. By End User
14.4. Key Takeaways
15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Treatment
15.2.3. By Disease Indication
15.2.4. By End User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Treatment
15.3.3. By Disease Indication
15.3.4. By End User
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Treatment
16.1.2.2. By Disease Indication
16.1.2.3. By End User
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Treatment
16.2.2.2. By Disease Indication
16.2.2.3. By End User
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Treatment
16.3.2.2. By Disease Indication
16.3.2.3. By End User
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Treatment
16.4.2.2. By Disease Indication
16.4.2.3. By End User
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Treatment
16.5.2.2. By Disease Indication
16.5.2.3. By End User
16.6. UK
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Treatment
16.6.2.2. By Disease Indication
16.6.2.3. By End User
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Treatment
16.7.2.2. By Disease Indication
16.7.2.3. By End User
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Treatment
16.8.2.2. By Disease Indication
16.8.2.3. By End User
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Treatment
16.9.2.2. By Disease Indication
16.9.2.3. By End User
16.10. Poland
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Treatment
16.10.2.2. By Disease Indication
16.10.2.3. By End User
16.11. Russia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Treatment
16.11.2.2. By Disease Indication
16.11.2.3. By End User
16.12. Czech Republic
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Treatment
16.12.2.2. By Disease Indication
16.12.2.3. By End User
16.13. Romania
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Treatment
16.13.2.2. By Disease Indication
16.13.2.3. By End User
16.14. India
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Treatment
16.14.2.2. By Disease Indication
16.14.2.3. By End User
16.15. Bangladesh
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Treatment
16.15.2.2. By Disease Indication
16.15.2.3. By End User
16.16. Australia
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Treatment
16.16.2.2. By Disease Indication
16.16.2.3. By End User
16.17. New Zealand
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Treatment
16.17.2.2. By Disease Indication
16.17.2.3. By End User
16.18. China
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Treatment
16.18.2.2. By Disease Indication
16.18.2.3. By End User
16.19. Japan
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Treatment
16.19.2.2. By Disease Indication
16.19.2.3. By End User
16.20. South Korea
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Treatment
16.20.2.2. By Disease Indication
16.20.2.3. By End User
16.21. GCC Countries
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Treatment
16.21.2.2. By Disease Indication
16.21.2.3. By End User
16.22. South Africa
16.22.1. Pricing Analysis
16.22.2. Market Share Analysis, 2022
16.22.2.1. By Treatment
16.22.2.2. By Disease Indication
16.22.2.3. By End User
16.23. Israel
16.23.1. Pricing Analysis
16.23.2. Market Share Analysis, 2022
16.23.2.1. By Treatment
16.23.2.2. By Disease Indication
16.23.2.3. By End User
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Treatment
17.3.3. By Disease Indication
17.3.4. By End User
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. B. Braun Medical Inc.
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Alliancells Bioscience Corporation Ltd.
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Histogen Inc.
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Stempeutics Research Pvt. Ltd.
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Epic Research & Diagnostics Inc.
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Theravance Biopharma R&D Inc.
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Sequana Medical AG
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. NovaShunt AG
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Conatus Pharmaceuticals Inc.,
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Merck Sharp & Dohme Corp.
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used20. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Disease Indication, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Disease Indication, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Disease Indication, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 13: Western Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Western Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 15: Western Europe Market Value (US$ Million) Forecast by Disease Indication, 2018 to 2033
Table 16: Western Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 17: Eastern Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: Eastern Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 19: Eastern Europe Market Value (US$ Million) Forecast by Disease Indication, 2018 to 2033
Table 20: Eastern Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 21: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: South Asia and Pacific Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 23: South Asia and Pacific Market Value (US$ Million) Forecast by Disease Indication, 2018 to 2033
Table 24: South Asia and Pacific Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 25: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 26: East Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 27: East Asia Market Value (US$ Million) Forecast by Disease Indication, 2018 to 2033
Table 28: East Asia Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 29: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 30: Middle East and Africa Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 31: Middle East and Africa Market Value (US$ Million) Forecast by Disease Indication, 2018 to 2033
Table 32: Middle East and Africa Market Value (US$ Million) Forecast by End User, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Disease Indication, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by End User, 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 9: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 11: Global Market Value (US$ Million) Analysis by Disease Indication, 2018 to 2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033
Figure 14: Global Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 15: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 17: Global Market Attractiveness by Treatment, 2023 to 2033
Figure 18: Global Market Attractiveness by Disease Indication, 2023 to 2033
Figure 19: Global Market Attractiveness by End User, 2023 to 2033
Figure 20: Global Market Attractiveness by Region, 2023 to 2033
Figure 21: North America Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 22: North America Market Value (US$ Million) by Disease Indication, 2023 to 2033
Figure 23: North America Market Value (US$ Million) by End User, 2023 to 2033
Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 29: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Disease Indication, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 37: North America Market Attractiveness by Treatment, 2023 to 2033
Figure 38: North America Market Attractiveness by Disease Indication, 2023 to 2033
Figure 39: North America Market Attractiveness by End User, 2023 to 2033
Figure 40: North America Market Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 42: Latin America Market Value (US$ Million) by Disease Indication, 2023 to 2033
Figure 43: Latin America Market Value (US$ Million) by End User, 2023 to 2033
Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) Analysis by Disease Indication, 2018 to 2033
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 57: Latin America Market Attractiveness by Treatment, 2023 to 2033
Figure 58: Latin America Market Attractiveness by Disease Indication, 2023 to 2033
Figure 59: Latin America Market Attractiveness by End User, 2023 to 2033
Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 61: Western Europe Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 62: Western Europe Market Value (US$ Million) by Disease Indication, 2023 to 2033
Figure 63: Western Europe Market Value (US$ Million) by End User, 2023 to 2033
Figure 64: Western Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 65: Western Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Western Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 69: Western Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 70: Western Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 71: Western Europe Market Value (US$ Million) Analysis by Disease Indication, 2018 to 2033
Figure 72: Western Europe Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033
Figure 73: Western Europe Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033
Figure 74: Western Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 75: Western Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 76: Western Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 77: Western Europe Market Attractiveness by Treatment, 2023 to 2033
Figure 78: Western Europe Market Attractiveness by Disease Indication, 2023 to 2033
Figure 79: Western Europe Market Attractiveness by End User, 2023 to 2033
Figure 80: Western Europe Market Attractiveness by Country, 2023 to 2033
Figure 81: Eastern Europe Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 82: Eastern Europe Market Value (US$ Million) by Disease Indication, 2023 to 2033
Figure 83: Eastern Europe Market Value (US$ Million) by End User, 2023 to 2033
Figure 84: Eastern Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 85: Eastern Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: Eastern Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 89: Eastern Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 90: Eastern Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 91: Eastern Europe Market Value (US$ Million) Analysis by Disease Indication, 2018 to 2033
Figure 92: Eastern Europe Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033
Figure 93: Eastern Europe Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033
Figure 94: Eastern Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 95: Eastern Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 96: Eastern Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 97: Eastern Europe Market Attractiveness by Treatment, 2023 to 2033
Figure 98: Eastern Europe Market Attractiveness by Disease Indication, 2023 to 2033
Figure 99: Eastern Europe Market Attractiveness by End User, 2023 to 2033
Figure 100: Eastern Europe Market Attractiveness by Country, 2023 to 2033
Figure 101: South Asia and Pacific Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 102: South Asia and Pacific Market Value (US$ Million) by Disease Indication, 2023 to 2033
Figure 103: South Asia and Pacific Market Value (US$ Million) by End User, 2023 to 2033
Figure 104: South Asia and Pacific Market Value (US$ Million) by Country, 2023 to 2033
Figure 105: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: South Asia and Pacific Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 109: South Asia and Pacific Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 110: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 111: South Asia and Pacific Market Value (US$ Million) Analysis by Disease Indication, 2018 to 2033
Figure 112: South Asia and Pacific Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033
Figure 113: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033
Figure 114: South Asia and Pacific Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 115: South Asia and Pacific Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 116: South Asia and Pacific Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 117: South Asia and Pacific Market Attractiveness by Treatment, 2023 to 2033
Figure 118: South Asia and Pacific Market Attractiveness by Disease Indication, 2023 to 2033
Figure 119: South Asia and Pacific Market Attractiveness by End User, 2023 to 2033
Figure 120: South Asia and Pacific Market Attractiveness by Country, 2023 to 2033
Figure 121: East Asia Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 122: East Asia Market Value (US$ Million) by Disease Indication, 2023 to 2033
Figure 123: East Asia Market Value (US$ Million) by End User, 2023 to 2033
Figure 124: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 125: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 126: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 127: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 128: East Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 129: East Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 130: East Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 131: East Asia Market Value (US$ Million) Analysis by Disease Indication, 2018 to 2033
Figure 132: East Asia Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033
Figure 133: East Asia Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033
Figure 134: East Asia Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 135: East Asia Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 136: East Asia Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 137: East Asia Market Attractiveness by Treatment, 2023 to 2033
Figure 138: East Asia Market Attractiveness by Disease Indication, 2023 to 2033
Figure 139: East Asia Market Attractiveness by End User, 2023 to 2033
Figure 140: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 141: Middle East and Africa Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 142: Middle East and Africa Market Value (US$ Million) by Disease Indication, 2023 to 2033
Figure 143: Middle East and Africa Market Value (US$ Million) by End User, 2023 to 2033
Figure 144: Middle East and Africa Market Value (US$ Million) by Country, 2023 to 2033
Figure 145: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 146: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 147: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 148: Middle East and Africa Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 149: Middle East and Africa Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 150: Middle East and Africa Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 151: Middle East and Africa Market Value (US$ Million) Analysis by Disease Indication, 2018 to 2033
Figure 152: Middle East and Africa Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033
Figure 153: Middle East and Africa Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033
Figure 154: Middle East and Africa Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 155: Middle East and Africa Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 156: Middle East and Africa Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 157: Middle East and Africa Market Attractiveness by Treatment, 2023 to 2033
Figure 158: Middle East and Africa Market Attractiveness by Disease Indication, 2023 to 2033
Figure 159: Middle East and Africa Market Attractiveness by End User, 2023 to 2033
Figure 160: Middle East and Africa Market Attractiveness by Country, 2023 to 2033
